Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Super Bowl Ads Pit Levitra Against Cialis; Viagra Stays On The Sidelines

This article was originally published in The Pink Sheet Daily

Executive Summary

Erectile dysfunction ads mark new milestone in short history of DTC advertising on TV. Metaphor and euphemisms dominate in Levitra and Cialis ads.

You may also be interested in...



Lilly/Icos' Cialis Is Only Drug To Play In The Super Bowl Commercial Game

Sixty-second "product and use" spot for the erectile dysfunction agent says that "all over the world, more and more men are discovering Cialis." Tadalafil was the only drug advertised during the championship game, unlike the 2004 Super Bowl, when a Cialis commercial went up against reminder ads for Levitra.

Lilly/Icos' Cialis Is Only Drug To Play In The Super Bowl Commercial Game

Sixty-second "product and use" spot for the erectile dysfunction agent says that "all over the world, more and more men are discovering Cialis." Tadalafil was the only drug advertised during the championship game, unlike the 2004 Super Bowl, when a Cialis commercial went up against reminder ads for Levitra.

Cialis Has Price Flexibility Due To Strong Market Demand, Icos Says

Lilly/Icos' sampling program has been successful, Icos says. Company predicts robust 40%-50% sales growth in 2005 for Cialis even with inventory de-stocking in the first quarter.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel